Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
Posted on: Tuesday, 2 June 2009, 05:00 CDT
"We are extremely pleased that Abbott has chosen to renew our relationship with this multi-year extension of our original agreement. This is a testament to the truly unique capabilities of the Xmatrx(R) platform, which allows for the automation of advanced molecular staining assays, from Microtome to Microscope," said Dr.
The Xmatrx(R) platform allows for the walk-away automation of the entire FISH assay workflow, from specimen pretreatment to final cover-slipping and is designed for optimal results with Abbott Molecular AutoFISH(TM) reagents and FISH technology.
The Xmatrx will be co-branded and marketed under a co-exclusive distribution agreement which calls for both parties to collaborate further in aiding adoption of FISH, IHC and ISH as primary tools in the emerging field of molecular diagnostics and personalized medicine. Under the terms of the agreement BioGenex will receive a multi-year minimum volume commitment from Abbott.
About Xmatrx
The Xmatrx(R) is an integrated system consisting of a flexible intelligent platform capable of full automation from "Microtome to Microscope" for any slide based assay, and specially formulated and optimized reagents, including primary antibodies, detection kits and appropriate consumables. The outcome of this approach provides a total solution capable of delivering reproducible and consistent results for IHC, ISH and FISH applications from baking through final cover-slipping.
About BioGenex
BioGenex provides products and services that support the molecular medicine testing continuum, from basic discovery, through translational research to IVD diagnostic testing. The company offers innovative instrument platforms and a broad range of reagents to standardize and bring workflow improvements to slide based assays; delivering solutions that provide the answers to the fundamental questions that lie at the heart of complex diseases. With a strong intellectual property portfolio the company intends to be a central player in the emerging molecular diagnostic and personalized medicine market place. The company is headquartered in
SOURCE BioGenex
Source: PR Newswire
Related Articles
- Syntermed Announces New Products and Agreements at Society of Nuclear Medicine Annual Meeting
- GE Healthcare Showcases Innovative Molecular Imaging Solutions at 2008 Society of Nuclear Medicine Conference
- CellCyte Signs Collaborative Agreement With Feinberg School of Medicine
- NanoString Technologies Announces Early Access Agreements With Baylor College of Medicine and University of Miami
- VGX Pharmaceuticals Announces DNA Therapeutics License Agreement With Baylor College of Medicine
- Calient Networks(R) and EdenTree Technologies(R) Sign Exclusive Reseller Agreement for Network Lab Automation Solutions
- Sequenom Reports Positive Outcomes From Two Siemens-Sponsored Molecular Diagnostic Research Studies of MassARRAY(R) Platform
- Immusol Announces an Exclusive Worldwide License Agreement With Baylor College of Medicine for a Novel Cancer Therapy
- TyRx Pharma, Inc., Announces the Signing of Exclusive License Agreement With Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center
- Christiana Care Health System Signs Agreement for Cereplex's Setnet Automated Surveillance Service
 |
 |
User Comments (0)
RSS Feeds